Healthcare provider profile · identity verified

Thomas Lloyd Edwards, D.O.

Family Practice · SAN ANTONIO, FL · NPI 1205879459

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Eliquis	Apixaban	321	32
Levothyroxine Sodium	Levothyroxine Sodium	310	56
Furosemide	Furosemide	287	46
Atorvastatin Calcium	Atorvastatin Calcium	230	52
Potassium Chloride	Potassium Chloride	227	39
Pantoprazole Sodium	Pantoprazole Sodium	219	46
Clopidogrel	Clopidogrel Bisulfate	187	25
Losartan Potassium	Losartan Potassium	153	26
Trazodone Hcl	Trazodone Hcl	119	31
Metoprolol Tartrate	Metoprolol Tartrate	110	25
Amlodipine Besylate	Amlodipine Besylate	108	23
Quetiapine Fumarate	Quetiapine Fumarate	107	15
Tamsulosin Hcl	Tamsulosin Hcl	102	28
Divalproex Sodium	Divalproex Sodium	97	17
Gabapentin	Gabapentin	93	19
Sertraline Hcl	Sertraline Hcl	92	19
Donepezil Hcl	Donepezil Hcl	91	19
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	83	12
Omeprazole	Omeprazole	77	suppressed
Sucralfate	Sucralfate	76	suppressed
Hydralazine Hcl	Hydralazine Hcl	75	14
Metoprolol Succinate	Metoprolol Succinate	73	18
Carvedilol	Carvedilol	71	13
Albuterol Sulfate	Albuterol Sulfate	70	13
Jardiance	Empagliflozin	68	suppressed
Lactulose	Lactulose	62	11
Alendronate Sodium	Alendronate Sodium	56	suppressed
Metformin Hcl	Metformin Hcl	54	suppressed
Enulose	Lactulose	52	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	49	13
Allopurinol	Allopurinol	48	suppressed
Nuedexta	Dextromethorphan Hbr/Quinidine	46	suppressed
Trulicity	Dulaglutide	46	suppressed
Levetiracetam	Levetiracetam	44	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	43	suppressed
Memantine Hcl	Memantine Hcl	43	suppressed
Gemtesa	Vibegron	42	suppressed
Mirtazapine	Mirtazapine	42	11
Fluvoxamine Maleate	Fluvoxamine Maleate	41	suppressed
Simvastatin	Simvastatin	41	suppressed
Lisinopril	Lisinopril	40	suppressed
Oxcarbazepine	Oxcarbazepine	38	suppressed
Famotidine	Famotidine	37	12
Humalog Kwikpen U-100	Insulin Lispro	37	suppressed
Amiodarone Hcl	Amiodarone Hcl	34	suppressed
Duloxetine Hcl	Duloxetine Hcl	33	suppressed
Midodrine Hcl	Midodrine Hcl	33	14
Breo Ellipta	Fluticasone/Vilanterol	31	suppressed
Latanoprost	Latanoprost	31	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	31	11
Buspirone Hcl	Buspirone Hcl	30	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	29	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	29	suppressed
Montelukast Sodium	Montelukast Sodium	29	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	28	21
Finasteride	Finasteride	28	suppressed
Ondansetron Hcl	Ondansetron Hcl	28	18
Timolol Maleate	Timolol Maleate	28	suppressed
Xarelto	Rivaroxaban	27	suppressed
Baclofen	Baclofen	26	suppressed
Ertapenem	Ertapenem Sodium	26	13
Linzess	Linaclotide	26	suppressed
Bumetanide	Bumetanide	25	suppressed
Glipizide	Glipizide	25	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	25	suppressed
Budesonide	Budesonide	24	suppressed
Clonidine Hcl	Clonidine Hcl	24	suppressed
Lovastatin	Lovastatin	24	suppressed
Prednisone	Prednisone	24	12
Valproic Acid	Valproic Acid (As Sodium Salt)	24	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	23	suppressed
Estradiol	Estradiol	23	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	23	suppressed
Nystatin	Nystatin	23	13
Procrit	Epoetin Alfa	23	suppressed
Paroxetine Hcl	Paroxetine Hcl	22	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	20	11
Brimonidine Tartrate	Brimonidine Tartrate	20	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	19	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	19	suppressed
Prazosin Hcl	Prazosin Hcl	19	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Gentamicin Sulfate	Gentamicin Sulfate	18	suppressed
Lamotrigine	Lamotrigine	18	suppressed
Risperidone	Risperidone	18	suppressed
Azithromycin	Azithromycin	17	12
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Fluticasone Propionate	Fluticasone Propionate	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Lubiprostone	Lubiprostone	16	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	16	suppressed
Restasis	Cyclosporine	16	suppressed
Diltiazem 24hr Er (La)	Diltiazem Hcl	15	suppressed
Glimepiride	Glimepiride	15	suppressed
Lidocaine Hcl	Lidocaine Hcl	15	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	14	suppressed
Ketoconazole	Ketoconazole	14	11
Mupirocin	Mupirocin	14	11
Anastrozole	Anastrozole	13	suppressed
Aranesp	Darbepoetin Alfa In Polysorbat	13	suppressed
Arformoterol Tartrate	Arformoterol Tartrate	13	suppressed
Ceftriaxone	Ceftriaxone Sodium	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Digoxin	Digoxin	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	suppressed
Fluconazole	Fluconazole	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	suppressed
Trimethoprim	Trimethoprim	13	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Fiasp Flextouch	Insulin Aspart (Niacinamide)	11	suppressed
Lidocaine Hcl	Lidocaine Hcl/Pf	11	suppressed
Liothyronine Sodium	Liothyronine Sodium	11	suppressed
Meloxicam	Meloxicam	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error